Contribute Try STAT+ Today

The biotech company Moderna invited the scrutiny of the world last month when it withheld key data on its in-development vaccine for the novel coronavirus. Stéphane Bancel, the company’s CEO, said Wednesday that Moderna’s decision to be vague was a matter of respecting federal securities laws and the rules of scientific journals.

Speaking at an online event held by the Wall Street firm Jefferies, Bancel said Moderna issued its May 18 press release — which described the vaccine’s beneficial effects only in qualitative terms — to prevent a potential leak. And the company left out key data so that the National Institutes of Health, which is conducting the vaccine trial, could later publish the results in a medical journal, he said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • so why not share the data now on the 42 patients.? they couldve waited 2 weeks. they were clearly pumping the stock for financing and exec sells

Comments are closed.